Loma Therapeutics ApS: Financial statements 2025
CVR: 44226189
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Loma Therapeutics ApS (CVR 44226189) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -483,088 and a net result of DKK -3,540,377. Equity in the 2025 report amounted to DKK -8,121,947. The company had 5 employees in the financial year.
- Gross Profit
- DKK -483,088
- Profit/Loss
- DKK -3,540,377
- Equity
- DKK -8,121,947
- Total Assets
- DKK 7,337,718
- Employees
- 5
Official annual report
How creditworthy is Loma Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Loma Therapeutics ApS has published its interim report for the period August 9, 2023 to December 31, 2024.
As of January 13, 2025, Alejandra Maria Cristina Bonifacini Mørk has joined the board of directors of Loma Therapeutics ApS.
As of January 13, 2025, Leif Helth Jensen has joined the board of directors of Loma Therapeutics ApS.
As of January 13, 2025, Stuart John Myles Collinson has joined the board of directors of Loma Therapeutics ApS.
As of January 13, 2025, Ralf Wagner has joined the board of directors of Loma Therapeutics ApS.
As of January 13, 2025, Northgaard Holding ApS is registered as an owner of Loma Therapeutics ApS with an ownership share of 5%.
About Loma Therapeutics ApS
Loma Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ditte Rahbæk Boilesen and Stephanie Holstein-Rønsbo. The board consists of Alejandra Maria Cristina Bonifacini Mørk (chair), Leif Helth Jensen, Ralf Wagner and Stuart John Myles Collinson. The company is owned by Northgaard Holding ApS, Ditte Boilesen Holding ApS and Holstein-Rønsbo Holding ApS. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK -483,088 and a net result of DKK -3,540,377. Equity in the 2025 report amounted to DKK -8,121,947.
